Armah, G.E.Cortese, M.M.Dennis, F.E.Yu, Y.Morrow, A.L.McNeal, M.M.Lewis, K.D.C.Awuni, D.A.Armachie, J.Parashar, U.D.2019-05-212019-05-212019-03https://doi.org/10.1093/infdis/jiy573Volume 219, Issue 5,Pages 746–749http://ugspace.ug.edu.gh/handle/123456789/30136Rotaviruses bind to enterocytes in a genotype-specific manner via histo-blood group antigens (HBGAs), which are also detectable in saliva. We evaluated antirotavirus immunoglobulin A seroconversion (‘vaccine take”) among 166 Ghanaian infants after 2–3 doses of G1P[8] rotavirus vaccine during a vaccine trial, by HBGA status from saliva collected at age 4.1 years. Only secretor status was associated with seroconversion: 41% seroconversion for secretors vs 13% for nonsecretors; relative risk, 3.2 (95% confidence interval, 1.2–8.1; P = .016). Neither Lewis antigen nor salivary antigen blood type was associated with seroconversion. Likelihood of “take” for any particular rotavirus vaccine may differ across populations based on HBGAs.enFUT2Lewis antigenRotavirusSecretorVaccineArticle